BetaGlue Therapeutics Receives Belgium Ministry of Health Approval for YntraDose® Clinical Trial in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC) Milan, December 15th, 2025 (GlobeNewswire) – BetaGlue® Therapeutics (“BetaGlue” or the…
read moreMilan, December 1st, 2025 (GlobeNewsire) BetaGlue Therapeutics Expands its Clinical Trial in Italy after obtaining approval from the Italian Ministry of Health to conduct clinical study in Unresectable Locally Advanced…
read moreMilan, November 12, 2025 (GlobeNewsire) – BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a clinical-stage oncology company developing an innovative radiotherapy solution for the targeted treatment of solid tumours, announced today…
read moreMilan, September 22, 2025 (GlobeNewsire) – BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid…
read moreMilan, May 27th 2025 – BetaGlue® Therapeutics S.p.A. (“BetaGlue”), a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumours, called YntraDose®,…
read moreMilan, February 20th 2025 – BetaGlue® Therapeutics S.p.A. (“BetaGlue”), a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumours, called YntraDose®,…
read moreMilan, December 16th 2024 - BetaGlue® Therapeutics S.p.A. (“BetaGlue”) an Italian clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumours, called…
read moreMilan, June 6, 2024 – BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a clinical-stage radiotherapy company developing novel products for the personalised treatment of solid tumour cancers today announces the closing…
read moreMilan, May 15, 2024 – BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a clinical-stage company developing novel radiotherapy products for the personalised treatment of solid tumour cancers today announces the appointment…
read moreMilan, April 30, 2024 – BetaGlue Technologies S.p.A. (“BetaGlue” or the “Company”) a clinical-stage company developing novel radiotherapy products for the personalised treatment of solid tumour cancers today announces the…
read more
